De Simone R, Irace L, Perna B, Caruso C, Guida M, Iacono A
Facoltà di Medicina e Chirurgia, Istituto Medico Chirurgico di Cardiologia Cattedra di Cardiologia, II Università degli Studi di Napoli.
Minerva Cardioangiol. 1993 May;41(5):205-9.
Of the main aspects of hypertension, left ventricular hypertrophy and appearance of cardiac dysfunction seem to be the most common and to produce an early and severe cardiac deterioration. Even in the presence of normal systolic function diastolic filling abnormalities are described. The efficacy of many antihypertensive drugs to decrease blood pressure and to reduce left ventricular hypertrophy has already been demonstrated. Cilazapril is a new ACE-inhibitor that in previous studies showed a very important antihypertensive effect. To assess its capacity, in long-term treatment, to reduce left ventricular hypertrophy we performed a prospective study on patients with mild hypertension.
Nineteen patients (aged 48 +/- 15 years) with mild hypertension (mean arterial pressure automatically recorded for 24 hours with blood pressure ambulatorial monitoring) were treated with cilazapril (5 mg/day) for 1 year. Doppler echocardiography was performed: at the beginning, after 6 months and after one year of therapy. The following parameters were evaluated: interventricular septal and posterior wall thickness, LV end-diastolic diameter, LV mass index, early (E) and late (A) diastolic filling flow velocities and the ratio E/A.
A significant decrease was observed in mean arterial pressure (from 130 +/- 14 mmHg at beginning to 102 +/- 11 mmHg at six months of therapy and to 103 +/- 9 mmHg at one year of therapy). A significant reduction in LV hypertrophy and an improved diastolic filling pattern of the left ventricle was shown after six months of therapy with cilazapril; this improvement still remained after 1 year of therapy.
In this study antihypertensive efficacy of cilazapril has been confirmed. Moreover, in long treatment, cilazapril has been useful to reduce left ventricular hypertrophy and to improve diastolic filling without significant side effects.
在高血压的主要方面中,左心室肥厚和心脏功能障碍的出现似乎最为常见,并会导致早期且严重的心脏功能恶化。即使在收缩功能正常的情况下,也有舒张期充盈异常的描述。许多抗高血压药物降低血压和减轻左心室肥厚的疗效已经得到证实。西拉普利是一种新型血管紧张素转换酶抑制剂,在先前的研究中显示出非常重要的降压作用。为了评估其在长期治疗中减轻左心室肥厚的能力,我们对轻度高血压患者进行了一项前瞻性研究。
19例轻度高血压患者(年龄48±15岁,通过动态血压监测自动记录24小时平均动脉压)接受西拉普利(5毫克/天)治疗1年。在治疗开始时、6个月后和1年后进行多普勒超声心动图检查。评估以下参数:室间隔和后壁厚度、左心室舒张末期直径、左心室质量指数、舒张早期(E)和晚期(A)充盈血流速度以及E/A比值。
平均动脉压显著降低(从治疗开始时的130±14毫米汞柱降至治疗6个月时的102±11毫米汞柱,以及治疗1年时的103±9毫米汞柱)。西拉普利治疗6个月后,左心室肥厚显著减轻,左心室舒张期充盈模式得到改善;这种改善在治疗1年后仍然存在。
在本研究中,西拉普利的降压疗效得到了证实。此外,在长期治疗中,西拉普利有助于减轻左心室肥厚并改善舒张期充盈,且无明显副作用。